The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.

Source: https://www.nytimes.com/2018/01/22/business/dealbook/sanofi-hemophilia-bioverativ.html?partner=rss